No Data
Guangzhou LBP Medicine Science & Technology's (SHSE:688393) Earnings Quality Is Low
An Biping: Third quarter report 2024
Third Quarter Report 2024
Guangzhou LBP Medicine Science & Technology (688393.SH) released its performance for the first three quarters, with a net income of 29.6308 million yuan, a decrease of 21.18% year-on-year.
Guangzhou LBP Medicine Science & Technology (688393.SH) released the report for the first three quarters of 2024, during the reporting period the company achieved revenue of 3...
Guangzhou LBP Medicine Science & Technology (688393.SH) obtained multiple qualifications from July to September.
Guangzhou LBP Medicine Science & Technology (688393.SH) announced that the company and its subsidiaries obtained domestic medical...
Guangzhou LBP Medicine Science & Technology (688393.SH): Obtained 6 domestic medical instruments registration/filing certificates, obtained 9 intellectual property qualifications, obtained 7 overseas certifications from July to September.
Guangzhou LBP Medicine Science & Technology (688393.SH) announced on October 11th that the company and its subsidiaries obtained 6 domestic medical device registration/filing certificates, 9 intellectual property qualifications, and 7 overseas certifications from July to September 2024. The acquisition of the above qualifications is beneficial for enriching the company's product range, improving the company's intellectual property protection system, expanding the company's product layout in the field of tumor screening and accurate diagnosis, and further enhancing the company's core competitiveness.
Risks Still Elevated At These Prices As Guangzhou LBP Medicine Science & Technology Co., Ltd. (SHSE:688393) Shares Dive 26%No Data
No Data
